Economics Faculty Database
Economics
Arts & Sciences
Duke University
 HOME > Arts & Sciences > Economics > Faculty    Search Help Login pdf version printable version 

Publications of Henry G. Grabowski    :chronological  alphabetical  combined  bibtex listing:

Monographs

  1. with Richard Manning, Key economic and value considerations in the U.S. market for plasma protein therapies (February, 2018), Bates White Economic Consulting [view]
  2. "Patents and New Product Development in the Pharmaceuticals and Biotechnology Industries", edited by John Duca, Science and Cents: The Economics of Biotechnology (87-104), Federal Reserve Bank of Dallas [PDF]
  3. The Search for New Vaccines: The Effects of the Vaccines for Children Program (1997), American Enterprise Institute for Public Policy Research: Washington, D.C.
  4. Health Care Cost Containment and Pharmaceutical Innovation (1986), pp. 25-28, Proceedings of the Conferences on Health Care and the Elderly, Washington, D.C.
  5. with John Vernon, The Regulation of Pharmaceuticals: Balancing the Benefits and Risks (1983), American Enterprise Institute for Public Policy Research: Washington, D.C.
  6. The Effects of Product Quality Regulation on Innovation in the U.S. Pharmaceutical Industry (1979), Final Report for the National Science Foundation Grant PRA 75-19823 (National Technical Information Services, Washington, D.C.)
  7. with John Vernon, The Impact of Regulation on Industrial Innovation (1979), National Academy of Sciences: Washington, D.C.
  8. The Effects of Advertising on the Interindustry Distribution of Demand, Occasional Papers of National Bureau of Economic Research, Explorations in Economic Research, vol. 3 (Winter, 1976), pp. 21-75
  9. Drug Regulation and Innovation: Empirical Evidence and Policy Options (1976), American Enterprise Institute for Public Policy Research: Washington, D.C.

Journal Articles

  1. H.G. Grabowski, C. Brain , A. Taub and R. Guha, Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes, American Journal of Health Economics, vol. 3 no. 1 (Winter, 2017), pp. 33-59 [AJHE_a_00066], [doi]
  2. Grabowski, HG; Marriott, Z; Kovacheva, P; Elzinga, A, One Year after the Launch of the First U.S. Biosimilar Drug: Lessons for the Future? (August, 2017)
  3. Grabowski, H; Brain, C; Taub, A; Guha, R, Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes, American Journal of Health Economics, vol. 3 no. 1 (February, 2017), pp. 33-59, University of Chicago Press [doi]
  4. Grabowski, H; Long, G; Mortimer, R; Boyo, A, Updated trends in US brand-name and generic drug competition, Journal of Medical Economics, vol. 19 no. 9 (September, 2016), pp. 836-844, Informa UK Limited [doi]
  5. Grabowski, HG; Manning, RL, An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors, International Journal of the Economics of Business, vol. 23 no. 2 (May, 2016), pp. 149-166, Informa UK Limited [doi]  [abs]
  6. DiMasi, JA; Grabowski, HG; Hansen, RW, Innovation in the pharmaceutical industry: New estimates of R&D costs., Journal of health economics, vol. 47 (May, 2016), pp. 20-33 [doi]  [abs]
  7. Grabowski, HG; Skinner, MW; Hoppe, PAH; Manning, R; Tachdjian, R; Crone, JF; Younger, SJ, Risk-based decision making and ethical considerations in donor compensation for plassma-derived medicinal products, Transfusion, vol. 00 no. 11 (March, 2016), pp. 2889-2894, Wiley: 12 months [doi]
  8. Lietzan, EF; Grabowski, HG, FDA Regulation of Biosimilars (September, 2015)  [abs]
  9. DiMasi, JA; Grabowski, HG; Hansen, RW, The cost of drug development., The New England journal of medicine, vol. 372 no. 20 (May, 2015), pp. 1972 [doi]
  10. with Grabowski, HG; DiMasi, JA; Long, G, The roles of patents and research and development incentives in biopharmaceutical innovation., Health affairs (Project Hope), vol. 34 no. 2 (February, 2015), pp. 302-310 [doi]  [abs]
  11. with Grabowski, HG; Guha, R; Salgado, M, Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future., Health affairs (Project Hope), vol. 33 no. 6 (June, 2014), pp. 1048-1057 [doi]  [abs]
  12. with Grabowski, H; Guha, R; Salgado, M, Biosimilar competition: lessons from Europe, Nature Reviews Drug Discovery, vol. 13 no. 2 (February, 2014), pp. 99-100, Springer Science and Business Media LLC [doi]
  13. with Grabowski, HG; Long, G; Mortimer, R, Recent Trends in Brand-Name and Generic Drug Competition, Journal of Medical Economics, vol. 1-8 (2013), pp. 1-8, Taylor & Francis: STM, Behavioural Science and Public Health Titles
  14. with Grabowski, H; Lewis, T; Guha, R; Ivanova, Z; Salgado, M; Woodhouse, S, Does generic entry always increase consumer welfare?, Food and drug law journal, vol. 67 no. 3 (January, 2012), pp. 373-ii  [abs]
  15. with Grabowski, HG; Kyle, M; Mortimer, R; Long, G; Kirson, N, Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act., Health affairs (Project Hope), vol. 30 no. 11 (November, 2011), pp. 2157-2166 [22068409], [doi]  [abs]
  16. Grabowski, HG, The Evolution of the Pharmaceutical Industry Over the Past 50 Years: A Personal Reflection, International Journal of the Economics of Business, vol. 18 no. 2 (July, 2011), pp. 161-176 [repository]
  17. with Grabowski, Henry, ; Long, G; Mortimer, R, Data Exclusivity for Biologics, Nature Reviews Drug Discovery, vol. 10 no. 1 (January, 2011), pp. 15-16 (PDF also includes the on-line supplementary material published in connection with this article..) [repository]
  18. with Grabowski, Henry, ; Long, G; Mortimer, R, Implementation of the Biosimilar Pathway: Economic and Policy Issues, Seton Hall Law Review, vol. 41 no. 2 (2011), pp. 511-557 [repository]
  19. Moe, J; Grabowski, H; Ridley, D, FDA review vouchers., The New England journal of medicine, vol. 360 no. 8 (February, 2009), pp. 837 [doi]
  20. Baker-Smith, CM; Benjamin, DK; Grabowski, HG; Reid, ED; Mangum, B; Goldsmith, JV; Murphy, MD; Edwards, R; Eisenstein, EL; Sun, J; Califf, RM; Li, JS, The economic returns of pediatric clinical trials of antihypertensive drugs., Am Heart J, vol. 156 no. 4 (October, 2008), pp. 682-688 [doi]  [abs]
  21. Grabowski, HG, Follow-on biologics: data exclusivity and the balance between innovation and competition, Nature Reviews Drug Discovery, vol. 7 no. 6 (June, 2008), pp. 479-488 [repository]
  22. with Grabowski, H; Wang, YR, Do faster food and drug administration drug reviews adversely affect patient safety? An analysis of the 1992 prescription drug user fee act, Journal of Law and Economics, vol. 51 no. 2 (May, 2008), pp. 377-406, University of Chicago Press, ISSN 0022-2186 [Gateway.cgi], [doi]  [abs]
  23. Dimasi, JA; Hansen, RW; Grabowski, HG, Misleading congress about drug development: Reply., Journal of health politics, policy and law, vol. 33 no. 2 (April, 2008), pp. 319-324 [doi]  [abs]
  24. with Jeffrey L. Moe, Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention, Cancer Prevention Research (2008) [PDF]
  25. with DiMasi, JA; Grabowski, HG, Should the patent system for new medicines be abolished?, Clinical pharmacology and therapeutics, vol. 82 no. 5 (November, 2007), pp. 488-490, ISSN 0009-9236 [Gateway.cgi], [doi]
  26. with Moe, JL, Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention, Duke Department of Economics Working Papers, vol. 1 no. 2 (November, 2007), pp. 84-90 [19138940], [doi]  [abs]
  27. with Grabowski, HG; Kyle, M, Generic competition and market exclusivity periods in pharmaceuticals, Managerial and Decision Economics, vol. 28 no. 4-5 (June, 2007), pp. 491-502, WILEY [repository], [doi]  [abs]
  28. with Dimasi, JA; Grabowski, HG, The cost of biopharmaceutical R&D: Is biotech different?, Managerial and Decision Economics, vol. 28 no. 4-5 (June, 2007), pp. 469-479, WILEY [repository], [doi]  [abs]
  29. with Grabowski, HG; Ridley, DB; Schulman, KA, Entry and competition in generic biologics, Managerial and Decision Economics, vol. 28 no. 4-5 (June, 2007), pp. 439-451, WILEY, ISSN 0143-6570 [repository], [doi]  [abs]
  30. DiMasi, JA; Grabowski, HG, In reply [2], Journal of Clinical Oncology, vol. 25 no. 16 (June, 2007), pp. 2331, American Society of Clinical Oncology (ASCO) [doi]
  31. with Li, JS; Eisenstein, EL; Grabowski, HG; Reid, ED; Mangum, B; Schulman, KA; Goldsmith, JV; Murphy, MD; Califf, RM; Benjamin, DK, Economic return of clinical trials performed under the pediatric exclusivity program., JAMA, vol. 297 no. 5 (February, 2007), pp. 480-488 [17284698], [doi]  [abs]
  32. with DiMasi, JA; Grabowski, HG, Economics of new oncology drug development., Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 25 no. 2 (January, 2007), pp. 209-216, ISSN 0732-183X [Gateway.cgi], [doi]  [abs]
  33. with Gokcekus, O; Adams, M; Grabowski, H; Tower, E, How did the 2003 prescription drug re-importation bill pass the house?, Economics and Politics, vol. 18 no. 1 (March, 2006), pp. 27-45, WILEY, ISSN 0954-1985 [repository], [doi]  [abs]
  34. with Grabowski, HG; Wang, YR, The quantity and quality of worldwide new drug introductions, 1982-2003., Health affairs (Project Hope), vol. 25 no. 2 (March, 2006), pp. 452-460 [16522586], [doi]  [abs]
  35. with Saha, A; Grabowski, Henry, ; Birnbaum, H; Greenberg, P; Bizan, O, Generic Competition in the U.S. Pharmaceutical Industry, International Journal of the Economics of Business, vol. 13 no. 1 (February, 2006), pp. 15-38, Informa UK Limited (Vol. 13, Issue 1, pp. 15-38.) [repository], [doi]  [abs]
  36. with Cockburn, I; Long, G, The Market for Follow-On Biologics: How Will It Evolve?, Health Affairs, vol. 25 no. 5 (2006), pp. 1291-1301 [repository]
  37. with Ridley, DB; Grabowski, HG; Moe, JL, Developing drugs for developing countries., Health Aff (Millwood), vol. 25 no. 2 (2006), pp. 313-324 [16522573], [doi]  [abs]
  38. with Ridley, DB; Kramer, JM; Tilson, HH; Grabowski, HG; Schulman, KA, Spending on postapproval drug safety., Health Aff (Millwood), vol. 25 no. 2 (2006), pp. 429-436 [16522583], [doi]  [abs]
  39. with Light, DW; Warburton, RN, Extraordinary claims require extraordinary evidence., Journal of health economics, vol. 24 no. 5 (September, 2005), pp. 1030-1033, Elsevier BV, ISSN 0167-6296 [Gateway.cgi], [doi]
  40. with DiMasi, JA; Hansen, RW; Grabowski, HG, Setting the record straight on setting the record straight: Response to the Light and Warburton rejoinder, Journal of Health Economics, vol. 24 no. 5 (September, 2005), pp. 1049-1053, Elsevier BV, ISSN 0167-6296 [Gateway.cgi], [doi]
  41. Light, DW; Warburton, RN; DiMasi, JA; Hansen, RW; Grabowski, HG, Setting the record straight in the reply by DiMasi, Hansen and Grabowski, Journal of Health Economics, vol. 24 no. 5 (January, 2005), pp. 1045-1048, Elsevier BV [doi]
  42. H.G. Grabowski, Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act, in Cambridge University Press Conference Volume, edited by Jerome Reichman (2005), pp. 457-480 [PDF] [abs]
  43. Grabowski, HG, Encouraging the Development of New Vaccines, Health Affairs, vol. 24 no. 3 (2005), pp. 697-704 [repository]
  44. Grabowski, HG, Are the Economics of Pharmaceutical R&D Changing? Productivity, Patents and Political Pressures, PharmacoEconomics, vol. 22, suppl. 2 (2004), pp. 15-24 [repository]  [abs]
  45. with DiMasi, JA; Grabowski, HG; Vernon, J, R&D costs and returns by therapeutic category, DRUG INFORMATION JOURNAL, vol. 38 no. 3 (2004), pp. 211-223, ISSN 0092-8615 [Gateway.cgi], [doi]  [abs]
  46. Grabowski, HG, The Ripple Effects of a Restrictive Medicaid Formulary (editorial), American Journal of Managed Care, vol. 9 no. 10 (October, 2003), pp. 648-649 [repository]
  47. Grabowski, HG, Patents and New Product Development in the Pharmaceutical and Biotechnology Industry, The Georgetown Public Policy Review, vol. 8 no. 2 (Spring, 2003), pp. 7-23 [repository]
  48. with DiMasi, JA; Hansen, RW; Grabowski, HG, The price of innovation: new estimates of drug development costs., Journal of health economics, vol. 22 no. 2 (March, 2003), pp. 151-185, ELSEVIER SCIENCE BV [repository], [doi]  [abs]
  49. Grabowski, HG, Patents, Innovation and Access to New Pharmaceuticals, Journal of International Economic Law (February, 2002), pp. 849-860 (Also presented at the American Association for the Advancement of Science, Annual Meetings, Boston.) [repository]
  50. with Grabowski, Henry, ; Vernon, J; DiMasi, J, Returns on R&D for 1990s New Drug Introductions, PharmacoEconomics, vol. 20 no. Supplement 3 (2002) [repository]
  51. Allen, JR; Anthony, CJ; Bosco, LA; Burke, LB; Byrns, PJ; Casnoff, CA; Clark, D; Fishburn, B; Fulda, TR; Gagnon, JP; Golodner, LF; Gondek, K; Grabowski, H; Grezlak, CR; Gross, DJ; Katz, E; Lawrence, E; Lipton, HL; Maine, LL; Matsumoto, J; McKercher, PL; Miller, M; Morris, L; Novitch, M; Palumbo, FB; Penna, PM; Persinger, GS; Pollard, M; Rucker, TD; Schur, C; Schweitzer, SO; Schulke, DG; Schulman, KA; Seidman, RC; Shulman, SA; Sleath, BL; Whitehouse, J; Wilford, BB; Williams, K; Woosley, RL, A framework for research and evaluation into the effects of managed care on the pharmaceutical marketplace: Excerpts from the final report, Journal of Research in Pharmaceutical Economics, vol. 10 no. 4 (January, 2001), pp. 235-263
  52. with Grabowski, HG; Vernon, J, The distribution of sales revenues from pharmaceutical innovation., PharmacoEconomics, vol. 18 Suppl 1 no. suppl. 1 (January, 2000), pp. 21-32, ISSN 1170-7690 [Gateway.cgi], [doi]  [abs]
  53. Grabowski, HG; Vernon, JM, Effective patent life in pharmaceuticals, International Journal of Technology Management, vol. 19 no. 1 (January, 2000), pp. 98-120, Inderscience Publishers (U.S. House of Representatives Colloquium for House Staff Members.) [doi]  [abs]
  54. with Grabowski, Henry, ; John Vernon, , Effective Patent Life in Pharmaceuticals, International Journal of Technology Management, vol. 19 no. 1/2 (2000), pp. 98-120 [repository]  [abs]
  55. with Grabowski, Henry, ; John Vernon, , The Determinants of Pharmaceutical Research and Development Expenditures, Journal of Evolutionary Economics, vol. 10 (2000), pp. 201-215 [repository]
  56. Grabowski, HG, The Role of Cost-Effectiveness Analysis in Managed Care Decisions, Pharmacoeconomics, vol. 14,suppl. 1 (1998), pp. 15-24 [repository]
  57. with Frank Sloan, , "The Impact of Cost-Effectiveness on Public and Private Policies in Health Care: An International Perspective", Social Science & Medicine, vol. 45 no. 4 (August, 1997), pp. 505-510 (Edited Symposium Volume.) [doi]
  58. with Grabowski, Henry, ; Mullins, CD, Pharmacy Benefit Management, Cost-Effectiveness Analysis and Drug Formulary Decisions, Social Science & Medicine, vol. 45 no. 4 (August, 1997), pp. 535-544 [repository]
  59. Grabowski, HG, The Effect of Pharmacoeconomics on Company Research and Development Decisions, PharmacoEconomics, vol. 11 no. 5 (May, 1997), pp. 389-397
  60. Sloan, FA; Grabowski, HG, Conclusions and implications, Social Science and Medicine, vol. 45 no. 4 (January, 1997), pp. 645-647 [doi]
  61. Sloan, FA; Grabowski, HG, The Impact of Cost-Effectiveness on Public and Private Policies in Health Care: An International Perspective: Introduction and overview, edited by Sloan, FA; Grabowski, H, Social Science and Medicine, vol. 45 no. 4 (1997), pp. 505-510, Pergamon Press Ltd. [doi]
  62. Grabowski, HG, Longer Patents for Increased Genetic Competition: The Waxman-Hatch Act After One Decade, PharmacoEconomics, vol. 10,Suppl. 2 (1996), pp. 110-123 [repository]
  63. with DiMasi, JA; Vernon, J; Grabowski, Henry, , R&D Costs, Innovative Output and Firm Size in the Pharmaceutical Industry, International Journal of the Economics of Business, vol. 2 no. 2 (1995), pp. 201-219, Informa UK Limited (Special volume honoring Merton J. Peck of Yale University.) [repository], [doi]  [abs]
  64. with DiMasi, J; Hansen, R; Lasagna, L, Research and Development Costs for New Drugs by Therapeutic Category: A Study of the U.S. Pharmaceutical Industry, PharmacoEconomics, vol. 7 no. 2 (1995), pp. 152-169
  65. with Grabowski, HG; Vernon, JM, Returns to R&D on new drug introductions in the 1980s., Journal of health economics, vol. 13 no. 4 (December, 1994), pp. 383-406, ISSN 0167-6296 [10140531], [doi]  [abs]
  66. with Grabowski, Henry, ; John Vernon, , Innovation and Structural Change in Pharmaceuticals and Biotechnology, Industrial and Corporate Change, vol. 3 no. 2 (1994), pp. 435-449 [repository]
  67. Grabowski, HG, Health Reform and Pharmaceutical Innovation, Seton Hall Law Review, vol. 24 no. 3 (1994), pp. 1221-1259 [repository]
  68. with Grabowski, HG; Vernon, JM, Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act, The Journal of Law and Economics, vol. 35 no. 2 (October, 1992), pp. 331-350, University of Chicago Press, ISSN 0022-2186 [Gateway.cgi], [doi]
  69. with The Costs and Returns to Pharmaceutical Research and Development, Rivista internazionale di scienze sociali, vol. 3 (September, 1992), pp. 347-357 [PDF]
  70. Grabowski, HG, The Costs and Returns to Pharmaceutical Research and Development, Revista Internazionale di Scienze sociali (International Social Studies Review) (September, 1992), pp. 347-358 [repository]
  71. with Grabowski, HG; Schweitzer, SO; Shiota, SR, The effect of Medicaid formularies on the availability of new drugs., PharmacoEconomics, vol. 1 no. Suppl 1 (January, 1992), pp. 32-40, ISSN 1170-7690 [10146929], [doi]  [abs]
  72. with DiMasi, JA; Hansen, RW; Grabowski, HG; Lasagna, L, Cost of innovation in the pharmaceutical industry., Journal of health economics, vol. 10 no. 2 (July, 1991), pp. 107-142, ISSN 0167-6296 [Gateway.cgi], [doi]  [abs]
  73. with Grabowski, Henry, ; John Vernon, , A New Look at the Returns and Risks to Pharmaceutical R & D, Management Science, vol. 36 no. 7 (July, 1990), pp. 804-821 [repository]
  74. Grabowski, HG; Vernon, J, A New Look at the Returns and Risks to Pharmaceutical R & D (July, 1990)
  75. with Grabowski, Henry, ; Viscusi, WK; Evans, WN, Price and Availability Tradeoffs of Automobile Insurance Regulation, Journal of Risk and Insurance, vol. LVI no. 2 (June, 1989), pp. 275-299 [repository]
  76. GRABOWSKI, HG, AN ANALYSIS OF UNITED-STATES INTERNATIONAL COMPETITIVENESS IN PHARMACEUTICALS, MANAGERIAL AND DECISION ECONOMICS (March, 1989), pp. 27-33, JOHN WILEY & SONS LTD, ISSN 0143-6570 [Gateway.cgi]
  77. Grabowski, HG, Medicaid Patients' Access to New Drugs, Health Affairs (Winter, 1988), pp. 102-114 [repository]
  78. with Grabowski, HG; Vernon, JM, Pioneers, Imitators, and Generics--A Simulation Model of Schumpeterian Competition, The Quarterly Journal of Economics, vol. 102 no. 3 (August, 1987), pp. 491-491, Oxford University Press (OUP), ISSN 0033-5533 [Gateway.cgi], [doi]
  79. Grabowski, HG, The Health/Economic Benefits of Drug Therapy: Efficacy, Low Risk, Cost Effectiveness, Patient Information and Emancipation, Swiss Pharma, vol. 9 no. 3a (1987), pp. 29-31
  80. with John Vernon, , Longer Patents for Lower Imitation Barriers: The 1984 Drug Act, The American Economic Review, vol. 76 no. 2 (May, 1986), pp. 195-198 [repository]
  81. Grabowski, HG, Issues of drug development: orphan drugs., Science (New York, N.Y.), vol. 228 no. 4702 (May, 1985), pp. 981 [doi]
  82. with Gort, M; McGuckin, R, Organizational Capital and the Choice between Specialization and Diversification, Managerial and Decision Economics, vol. 6 no. 1 (March, 1985), pp. 2-10
  83. Grabowski, HG, The Impact of Patent and Regulatory Policies on Drug Innovation, Medical Marketing & Media, vol. 18 no. 10 (October, 1983), pp. 42-63
  84. H.G. Grabowski with Richard J. Arnould, Automobile Safety Regulation: A Review of the Evidence, edited by Richard O. Zerbe, Research in Law and Economics, vol. 5 (1983), pp. 233-267
  85. Grabowski, HG, Public Policy and Pharmaceutical Innovation, Health Care Financing Review, vol. 4 no. 1 (September, 1982), pp. 75-87
  86. with John Vernon, , A Sensitivity Analysis of Expected Profitability of Pharmaceutical Research and Development, Managerial and Decision Economics, vol. 3 no. 1 (March, 1982), pp. 36-40 [repository]
  87. Grabowski, HG, Public Policy and Innovation: The Case of Pharmaceuticals, Technovation, vol. 1 (1982), pp. 157-189
  88. with Arnould, RJ, Auto Safety Regulation: An Analysis of Market Failure, The Bell Journal of Economics, vol. 12 no. 1 (Spring, 1981), pp. 27-48
  89. with GRABOWSKI, HG; VERNON, JM, SUBSTITUTION LAWS AND INNOVATION IN THE PHARMACEUTICAL-INDUSTRY, LAW AND CONTEMPORARY PROBLEMS, vol. 43 no. 1 (January, 1979), pp. 43-66, DUKE UNIV, ISSN 0023-9186 [Gateway.cgi]
  90. GRABOWSKI, HG, IMPACT OF REGULATION ON INNOVATION, FOOD AND DRUG LAW JOURNAL, vol. 34 no. 10 (January, 1979), pp. 555-560, FOOD DRUG LAW INST [Gateway.cgi]
  91. Grabowski, HG; Vernon, JM, SUBSTITUTION LAWS AND INNOVATION IN THE PHARMACEUTICAL-INDUSTRY (1979)
  92. Grabowski, HG, The Effects of Advertising on IntraIndustry Shifts on Demand, Occasional Papers of the National Bureau of Economic Research, Explorations in Economic Research, vol. 4 no. 5 (Fall, 1978), pp. 675-701
  93. with Grabowski, HG; Vernon, JM, Consumer product safety regulation, American Economic Review, vol. 68 no. 2 (January, 1978), pp. 284-289, ISSN 0002-8282 [Gateway.cgi]  [abs]
  94. with Grabowski, HG; Vernon, JM; Thomas, LG, Estimating the effects of regulation on innovation: an international comparative analysis of the pharmaceutical industry., The Journal of law & economics, vol. 21 no. 1 (January, 1978), pp. 133-163, ISSN 0022-2186 [Gateway.cgi], [doi]
  95. GRABOWSKI, HG, EFFECTS OF SUBSTITUTION LAWS ON INNOVATION, DRUG THERAPY, vol. 8 no. 12 (January, 1978), pp. 91-&, CORE MEDICAL JOURNALS
  96. with Grabowski, HG; Mueller, DC, Industrial Research and Development, Intangible Capital Stocks, and Firm Profit Rates, The Bell Journal of Economics, vol. 9 no. 2 (Fall, 1978), pp. 328-328, JSTOR, ISSN 0361-915X [Gateway.cgi], [doi]
  97. with Grabowski, HG; Thomas, LG; Vernon, JM, Estimating the effects of regulation on innovation: an international comparative analysis of the pharmaceutical industry., vol. 21 no. 1 (1978), pp. 133-163
  98. with GRABOWSKI, HG; VERNON, JM, CONSUMER-PROTECTION REGULATION IN ETHICAL DRUGS, AMERICAN ECONOMIC REVIEW, vol. 67 no. 1 (January, 1977), pp. 359-364, AMER ECONOMIC ASSOC, ISSN 0002-8282 [Gateway.cgi]
  99. with Grabowski, HG; Mueller, DC, Life-Cycle Effects on Corporate Returns on Retentions, The Review of Economics and Statistics, vol. 57 no. 4 (November, 1975), pp. 400-400, JSTOR, ISSN 0034-6535 [Gateway.cgi], [doi]
  100. with Baxter, ND, Rivalry in Research and Development: An Empirical Study, Journal of Industrial Economics, vol. 21 no. 2 (July, 1973), pp. 209-235
  101. with Corazzani, A; Dugan, D; Grabowski, Henry, , Determinants and Distributional Aspects of Enrollment in U.S. Higher Education, Journal of Human Resources, vol. 7 no. 1 (Winter, 1972), pp. 39-59 [repository]
  102. with Grabowski, Henry, ; Dennis Mueller, , Managerial and Stockholder Welfare Models of Firm Expenditures, Review of Economics and Statistics, vol. 54 (February, 1972), pp. 9-24 [repository]
  103. with Dennis Mueller, , Imitative Advertising in the Cigarette Industry, The Journal of American and Foreign Antitrust and Trade Regulations, vol. 16 no. 2 (Summer, 1971), pp. 257-292
  104. with Dennis Mueller, , Non-Price Competition in the Cigarette Industry: A Coment, Antitrust Bulletin, vol. 40 (Winter, 1970), pp. 257-292
  105. Grabowski, HG, Demand Shifting, Optimal Firm Growth, and Rule-of-Thumb Decision Making, Quarterly Journal of Econoics, vol. 84 (May, 1970), pp. 217-235 [repository]
  106. with Dennis Mueller, , Industrial Organization: The Role and Contribution of Econometrics, American Economic Review, vol. 60 no. 2 (May, 1970), pp. 100-104 [repository]
  107. with Grabowski, HG, The Determinents of Industrial Research and Development: A study of the chemical, drug, and petrolium industries, Journal of Political Economy, vol. 76 no. 2 (1968), pp. 292-306 (reprinted in K.S. Palda, ed., Readings in Managerial Economics, (Prentice-Hall), 1973; also reprinted in S. Yarney, ed., Economics of Industrial Structure: Selected Readings, (Penguine Modern Economics Series), 1973.) [repository]
  108. Grabowski, HG, The Determinents of Industrial Research and Development: A study of the chemical, drug, and petrolium industries (1968)

Chapters in Books

  1. Grabowski, HG, FDA in the Twenty-First Century, in FDA Regulation Of Biosimilars, edited by Cohen,, G; Lynch,, H (2015), pp. 414-430, Columbia University Press
  2. with Margaret Kyle, Mergers, Alliances and Acquisitions, in Encyclopedia of Health Economics, edited by Anthony Culyer (2014), Elsevier
  3. with Grabowski, HG; Long, G; Mortiner, R, Biosimilars, in Encyclopedia of Health Economics, edited by Culyer, A, vol. 1 (2014), pp. 86-97, Elsevier, San Diego
  4. Grabowski, HG, Pharmaceuticals and Health Care Costs (June, 2013) [repository]
  5. Grabowski, HG, The Contribution of the United States, Europe and Japan in Discovering New Drugs: 1982-2003, in Incentives for Research, Development, and Innovation in Pharmaceuticals, edited by Garcia-Fontes, WA (August, 2012), pp. 49-68, Springer, Barcelona, ISBN 9788493806217 [repository]
  6. with Grabowski, HG, Mergers, Accquisitions, and Alliances, in The Oxford Handbook of the Economics of the Biopharmaceutical Industry, edited by Danzon, PM; Nicholson, S (May, 2012), pp. 552-577, OUP USA, ISBN 9780199742998 [repository], [doi]  [abs]
  7. with DiMasi, Joseph A., ; Grabowski, HG, R&D Costs and Returns to New Drug Develoopment: A Review of the Evidence, in The Oxford Handbook of the Economics of the Biopharmaceutical Industry, edited by Danzon, PM; Nicholson, S (May, 2012), pp. 22-46, OUP USA, ISBN 9780199742998 [repository], [doi]  [abs]
  8. with Grabowski, HG; Ridley, David B., ; Moe, Jeffrey L., , Encouraging innovative treatment of neglected diseases through priority review vouchers, in Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific, edited by Eggleston, K (September, 2009), pp. 347-365, Stanford University: The Walter H, Shorenstein Asia-Pacific Research Center, Stanford University, ISBN 9781931368162 [repository]
  9. Grabowski, HG; Kyle, M, Mergers and Alliances in Pharmaceutical: Effects on Innovation and R&D Productivity, in The Economics of Corporate Governance and Mergers, edited by Gugler, K; Yurtoglu, B (January, 2008), pp. 262-287, Edward Elgar Publishing, ISBN 9781848443921 [repository]  [abs]
  10. with Margaret Kyle, Mergers and alliances in pharmaceuticals: effects on innovation and R&D productivity, in The Economics of Corporate Governance and Mergers, edited by Klaus Gugler and B. Burcin Yurtoglu (2008), pp. 262-287, Edward Elgar Publishing, Northampton, MA, ISBN 978 1 84720 719 [PDF]
  11. Grabowski, HG, Competition between Generic and Branded Drugs, in Pharmaceutical innovation: incentives, competition, and cost-benefit analysis in international perspective, edited by Sloan, FA; Hsieh, C-R (April, 2007), pp. 153-288, Cambridge University Press, ISBN 9780521874908 [repository]  [abs]
  12. Grabowski, HG, Increasing R&D Incentives for Neglected Diseases: Lessons from the Orphan Drug Act, in International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, edited by Maskus, KKE; Reichman, JJH (2005), pp. 457-480, Cambridge University Press, ISBN 9780521841962 (Published by Cambridge University Press (Conference volume).) [repository]  [abs]
  13. Grabowski, HG, Increasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act, in International Public Goods And Transfer Of Technology Under A Globalized Intellectual Property Regime, edited by Maskus, KKE; Reichman, JJH (2005), pp. 457-480, Cambridge University Press, ISBN 9780521841962 [repository]  [abs]
  14. Patents and the Development of New Pharmaceuticals in Pharmaceuticals and Biotechnology Industry, in Science and Cents: Exploring the Economics of Biotechnology, edited by Duca John V and Yucel, Mine K (2003), pp. 87-104, Federal Reserve Bank of Dallas (Proceedings of the 2002 Conference on Exploring the Economics of Biotechnology.) [PDF]
  15. with Grabowski, HG; Vernon, John, , Pressures from the Demand Side: Changing Market Dynamics and Industrial Structure, in Consolidation and Competition in the Pharmaceutical Industry, edited by Kettler, HE (2001), pp. 62-79, Office of Health Economics, ISBN 9781899040070 [repository]
  16. Grabowski, HG, Public Policy and Innovation in Pharmaceuticals and Biotechnology, in Business and Economics for the 21st Century Volume 1, edited by Kantarelis, D, vol. 1 (1997), pp. 343-349, Business and Economic Society International
  17. with Ronald W. Hansen, Economic Scales and Tests, in Quality of Life and Pharmacoeconomics in Clinical Trials, Second Edition, edited by B. Spilker (1996), pp. 79-84, Lippincott-Raven Press: Philadelphia
  18. with John Vernon, Returns to Pharmaceutical R&D: Prospects Under Health Care Reform, in Competitive Strategies in the Pharmaceutical Industry, edited by Robert Helms (1996), pp. 194-207, AEI Press: Washington, D.C.
  19. with Gary Zarkin, Josephine Mauskopf, Heather A. Bannerman, and Richard H. Weisler, Economic Evaluation of Drug Treatment for Psychiatric Disorders: The New Clinical Trial Protocol" Chapter 16, in Psychopharmacology: The Fourth Generation of Progress, edited by Floyd E. Bloom and David J. Kupfer (1995), pp. 1897-1905, Raven Press, Ltd.: NY [PDF]
  20. Zarkin, Gary A., ; Grabowski, HG; Mauskopf, Josephine, ; Bannerman, Heather A., ; Weisler, Ricard H., , Economic Evaluation of Drug Treatment for Psychiatric Disorders: The New Clinical Trial Protocol, in Psychopharmacology: the Fourth Generation of Progress, edited by Bloom, FE; ed, DJK (1995), pp. 1897-1905, Raven Press [repository]
  21. Grabowski, HG, 'Price and Profit Control, New Competitive Dynamics and the Economics of Innovation in the Pharmaceutical Industry', in Industrial Policy and the Pharmaceutical Industry, edited by Towse, A (1995), pp. 77-91, Office of Health Economics [repository]
  22. Grabowski, HG, The Changing Economics of Pharmaceutical Research and Development, in The Changing Economics of Medical Technology, edited by Gelijns, Annetine C., ; Halm, Ethan A., (January, 1991), pp. 35-52, National Academies Press, ISBN 9780309555944 [repository]
  23. Grabowski, HG, Product Liability in Pharmaceuticals: Comments on Chapters Eight and Nine, in The Liability Maze: The Impact of Liability Law on Safety and Innovation, edited by Huber, PPW; Litan, RE (1991), pp. 360-366, The Brookings Institution Press, ISBN 9780815737612 [repository]  [abs]
  24. with Ronald W. Hansen, Economic Scales and Tests, in Quality of Life Assessments in Clinical Trials, edited by B. Spilker (1990), pp. 61-69, Raven Press, Ltd.: New York
  25. Grabowski, HG, Innovation and International Competitiveness in Pharmaceuticals, in Evolving Technology and Market Structure: Studies in Schumpeterian Economics, edited by Heertje, Arnold, ; Perlman, Mark, (1990), pp. 167-185, University of Michigan Press [repository]
  26. with Lawrence De Brock, Economic Aspects of Vaccine Innovation and Manufacturing Chapter, in Vaccine Supply and Innovation (1985), pp. 45-64, National Academy Press: Washington, D.C.
  27. with Grabowski, HG; Vernon, John, , A Computer Simulation Model of Pharmaceutical Innovation, in Pharmaceutical Economics, edited by Lindgren, Bjorn, (1984), pp. 159-175, Swedish Institute for Health Economics and Liber Forlag, ISBN 9138613727 [repository]
  28. Grabowski, HG; Vernon, J, A Computer Simulation Model of Pharmaceutical Innovation, in Pharmaceutical Economics: Papers Presented at the 6. Arne Ryde Symposium, Helsingborg, Sweden 1982, edited by Lindgren, B (1984), pp. 159-175, Swedish Institute for Health Economics and Liber Forlag, ISBN 9789138613726 [repository]
  29. with Jean P. Gagnon, An Evaluation of the Maximum Allowable Cost Program, in The Effectiveness of Medicines in Containing Health Care Costs (1982), pp. 81-113, Proceedings of a Symposium of the National Pharmaceutical Council, Washington, D.C.
  30. with Grabowski, HG; Vernon, John, , The Pharmaceutical Industry, in Government and Technical Progress, edited by Nelson, RR; Policy, NYUGSOBACFSAT (1982), pp. 283-360, Pergamon [repository]
  31. Grabowski, HG; Vernon, JM, The Pharmaceutical Industry (1982), Pergamon
  32. with John Vernon, The Determinants of R&D Expenditures, in Drugs and Health, edited by Robert B. Helms (1981), pp. 3-20, American Enterprise Institute for Public Policy Research: Washington, D.C.
  33. Regulation and Industrial Innovation, in Industrial Innovation and Public Policy Options: Background Papers for a Colloquium (1981), pp. 65-81, National Academy Press: Washington, D.C.
  34. Regulation and the International Diffusion of Pharmaceuticals, in The International Supply of Medicines, edited by Robert B. Helms (1980), pp. 5-36, American Enterprise Institute for Public Policy Research: Washington, D.C.
  35. with John M. Vernon, New Studies on Market Definition, Concentration, Theory of Supply, Entry and Promotion, in Issues in Pharmaceutical Economics, edited by Robert I. Chien (1979), pp. 29-52, Lexington Books: Lexington, Mass.
  36. Regulation of the United States Pharmaceutical Industry: Current Problems and Policy Developments, in Medicines for the Year 2000, edited by George Teeling-Smith (1979), pp. 57-74, Office of Health Economics: London, England
  37. with John Vernon and Lacy Glenn Thomas, The Effects of Regulatory Policy on the Incentives to Innovate: An International Comparative Analysis, in Impact of Public Policy on Drug Innovation and Pricing, edited by Emery A. Link and Samuel Mitchell (1976), pp. 47-93, American University: Washington, D.C. [PDF]
  38. Grabowski, HG; Vernon, John, ; Thomas, Lacy Glenn, , Impact of Public Policy on Drug Innovation and Pricing, in Impact of Public Policy on Drug Innovation and Pricing, edited by Mitchell, SA; Link, E (1976), pp. 453 pages, American University [repository]
  39. with Grabowski, HG; Vernon, John M., , Structural Effects of Regulation on Innovation in the Ethical Drug Industry, in Essays on industrial organization, in honor of Joe S. Bain, edited by Bain, JS; Masson, RT; Qualls, PD (1976), pp. 181-205, Ballinger Publishing Company, ISBN 9780884104162 [repository]
  40. Advertising and Resource Allocation: A Critique, in Advertising and the Public Interest, edited by Salvatore F. Davita (1974), American Marketing Association
  41. with Oscar Morgenstern and R.W. Shepherd, A Graph-Oriented Model for Research Management, in Research Program Effectiveness, edited by M.C. Yovits, D.M. Gilford, E. Staveley and H.D. Lerner (1966), pp. 187-216, Gordon and Breach: New York [PD]
  42. Grabowski, HG, Graph-Oriented Model for Research Management, in Research program effectiveness. Proceedings of the conference sponsored by the Office of Naval Research, Washington, D.C., July 27-29, 1965. Edited by M. C. Yovits [and others], etc, edited by YOVITS, MC; Gilford, D.M., ; Staveley, E., ; Lerner, H.D., (1966), pp. 187-216, Gordon and Breach [repository]

Other

  1. H.G. Grabowski, FDA Regulation of Biosimilars (May, 2013) (Harvard Law School Conference on The FDA in the 21st Century.)
  2. H.G. Grabowski, Biosimilar Competition: Lessons From Europe and Prospects for the U.S. (May, 2013) (Office of Health Economics, London.)
  3. H.G. Grabowski, The Market for U.S. Biosimilars: Prospects and Lessons from Abroad (June, 2012) (American Society of Health Economists Meeting, Cornell University.)
  4. H.G. Grabowski, Paragraph IV Challenge Outcomes (July, 2011) (International Health Economics Association Meeting.)
  5. H.G. Grabowski, Economic and Policy Issues in Implementing a Biosimilar Pathway (January, 2010) (American Economic Association Meetings, Atlanta, Georgia.)
  6. H.G. Grabowski, Implementation of an Abbreviated Pathway for Biosimilars (January, 2010) (American Economic Association Meetings, Atlanta, Georgia..)
  7. H.G. Grabowski, Mergers and Alliances in Pharmaceuticals (November, 2009) (University of Pennsylvania Wharton School.)
  8. Returns to Pharmaceutical R&D in the 1990s (July, 2001) (Tufts University Conference, Center for the Study of Drug Development, Talloires France.)
  9. Patent Policy Issues in Pharmaceuticals (March, 2001) (Robert Wood Johnson Foundation Colloquium on the Pharmaceutical Industry, Washington, D.C..)
  10. New Research on the Returns to Pharmaceutical R & D (October, 2000) (American Enterprise Institute, Washington, D.C..)
  11. The Distribution of Sales Revenues from Pharmaceutical Innovation (June, 2000) (Schumpeterian Society Meetings, Manchester, England.)
  12. Health Reform and Pharmaceutical Innovation (1994), American Enterprise Institute for Public Policy Research: Washington, D.C. (American Enterprise Institute for Public Policy Research, Washington, D.C..)
  13. Testimony - Health Care Reform (1994) [PDF] [author's comments]
  14. Pharmaceuticals and Health Care Costs (October, 1993), Proceedings of the First International Health Care Forum, Health Care Policy and the Pharmaceutical Industry, Gotemba, Japan (International Health Care Forum, "Health Care Policy and the Pharmaceutical Industry," Gotemba, Japan.) [PDF]
  15. Pharmaceutical Research and Development: Return and Risk (1991), Centre for Medicines Research, Surrey, England (Sixth Annual Centre for Medicines Research Lecture, Centre for Medicine Research, Surrey, England.)
  16. Impact of Patent and Regulatory Policies on Drug Innovation, in Proceedings of the Second Annual Shearson Lehman Hutton Conference on Legal and Regulatory Issues Affecting Biotechnology and Health Care (October, 1988), pp. 5-16
  17. Studies on Drug Substitution, Patent Policy and Innovation in the Pharmaceutical Industry (1985) (Final report to the National Science Foundation available from the National Technical Information Services, Number PB-85-109700, Washington, D.C..)
  18. A Computer Simulation Model of Pharmaceutical Innovation, in Pharmaceutical Economics with John Vernon, edited by B. Lindgren (1982), Liber Forlag (Presented at the Arne Ryde Symposium Helsingborg, Sweden.) [PDF]
  19. Testimony - Patent Term Restoration Act of 1981 (1981) [PDF] [author's comments]
Duke University * Arts & Sciences * Economics * Faculty * Research * Staff * Master's * Ph.D. * Reload * Login